


COVID-19 – SKILLCELL, VOGO and INOVIE launch the first rapid integrated COVID-19 in-field testing solution in mid-June in France

After announcing the start of production and marketing of the EasyCov saliva test in their [25 May 2020 press release](#), the members of the SKILLCELL and VOGO consortium have signed a partnership with medical laboratory group and well-known diagnostics and screening specialist, INOVIE, to create the first integrated COVID-19 in-field testing solution in France. EasyCov is a saliva-based test that can detect the RNA virus of SARS-COV-2; it is a major innovation on the mechanisms currently available, combining several decisive attributes: rapid (results in under 60 minutes), painless, usable anywhere and suitable for mass testing.

Under this partnership, the screening solution, which combines the EasyCov test and a digital solution developed by VOGO, will be distributed and carried out by INOVIE, in field or in a laboratory, according to the needs expressed. Once the EasyCov test has been performed by a medical professional approved by INOVIE, the result is generated using colorimetric readings, via EasyCov Reader. The patient's results and health data will be transmitted in less than 60 minutes after approval by a medical biologist. This comprehensive, flexible test will be on the market from mid-June.



INOVIE is a key player in the “protect, test, isolate” approach required during the lockdown easing period, and has been actively involved in the screening of COVID-19 since the start of the health crisis. It presently has a testing capacity representing up to 20% of the PCR testing performed daily in France. The EasyCov test supplements and broadens INOVIE’s screening offering, allowing diagnosis by a medical biologist based on a saliva sample in under one hour

PRESS RELEASE

Paris, 27 May 2020

SKILL CELL
ALCEN



in a medical laboratory or in field. It means that INOVIE can provide rapid localised mass testing in situations such as sports competitions or checks for transport or within companies.

The combination of testing with a digital screening solution designed by VOGO is a major advantage for INOVIE. Using the automatic test analysis solution and the digital portal that is interoperable with INOVIE's laboratory information system (SIL), they can create a fully integrated and secure screening chain that meets the strictest of regulatory requirements set by the ministry of health, in conjunction with the screening information system, SI-DEP, a nationwide tool designed to computerise the screening process.

Alexandra Prioux, CEO of SKILLCELL, said:

"We are delighted to be part of this distribution partnership with INOVIE, a recognised player at the forefront of COVID-19 screening in France. This agreement is a major step for the consortium, which in under two months has succeeded in launching an efficient, economical and fully integrated screening chain. This achievement reflects the excellence of French know-how in the fields of scientific and technological innovation, healthcare and manufacturing."

Dr Thomas Hottier, joint CEO of INOVIE, commented:

"It is with great pride that we sign this agreement and participate in the distribution and performance of EasyCov testing in France. Screening requirements are growing with each passing week. The integration of the EasyCov medical test into our existing mechanism was an obvious move for INOVIE. When combined with a secure digital system this test brings together vital and unprecedented attributes in increasing our capacity and diversifying our screening offering: simple, painless, results in under 60 minutes, in-field usage and incorporating the VOGO solution for automated and rapid collection and distribution of results. We are eager to begin this collaboration with the consortium and to put all our medical expertise to work in the development and completion of these analyses in order to join the fight against COVID-19."

A production capacity of around 200,000 EasyCov kits a week has been determined at present, which can be rapidly expanded as order intake increases. The public price, incorporating all of INOVIE's services (contribution by medical biologists, outsourced logistics, reagents, after-sale technical service, etc.) will be set at a rate that is significantly lower than the PCR tests (€74 on average) currently on the market. This price may vary depending on conditions on the ground and the services carried out.

PRESS RELEASE

Paris, 27 May 2020

SKILL CELL
ALCEN



Press contact:

AGENCE PRPA - Danielle Maloubier
danielle.maloubier@prpa.fr
+33 (0)6 24 26 57 90

About EasyCov

Developed thanks to research by the CNRS SYS2DIAG laboratory, EasyCov is a saliva-based test that can be used in field with colorimetric readings in under an hour. The test is



performed by a healthcare professional and involves collecting less than 1ml of saliva from under the patient's tongue. The sample is deposited successively in two tubes heated to 65° using a nomadic device. The colorimetric reading screens the tested patients for the presence of the virus. A digital solution is used to present the results and to send them immediately to healthcare information systems. The EasyCov programme is supported by la Direction Générale de l'Armement (DGA), l'Agence de l'Innovation de Défense (AID), and by la Region Occitanie.

About SKILLCELL

An ALCEN group subsidiary. SkillCell develops in-field diagnostic tests using its simplicity-centred approach: tests that must be able to be used by anybody, anywhere and at any time. Founded in Guadeloupe in 2017, the company has offices in Jarry (Guadeloupe), Paris and Montpellier. The SkillCell team brings together scientific experts and seasoned manufacturers to find solutions to medical and societal diagnostic testing issues by providing relevant, high-quality information that allows users to make well-informed choices with full transparency. More information at: www.skillcell-alcen.com

Contact: presse@skillcell-alcen.com

About VOGO

VOGO develops, markets and distributes live & replay, audio and video solutions for spectators and professionals in sports arenas. The acquisition of Vokkero® in October 2019 enriched this range of professional solutions, with the integration of an internationally recognised line of audio communications systems in the world of sport (over 20 disciplines), as well as in industrial, service and entertainment sectors. All of the Group's technologies have patent protection. VOGO is present in France (Montpellier, Paris and Crolles) and in North America, with an office in New York. The Group has been listed on the Euronext Growth stock market since November 2018 (ISIN code: FR0011532225 - ALVGO). For more information: www.vogo-group.com

Contacts:

ACTIFIN – Financial Press Relations
Jennifer Julia
Email : jjullia@actifin.fr

ACTIFIN - Financial Communications
Victoire Demeestère / Stéphane Ruiz
Email : vdemeestere@actifin.fr

PRESS RELEASE

Paris, 27 May 2020

SKILL CELL
ALCEN



About INOVIE

Formed in 2010 by a group of doctors and pharmacists, the INOVIE group is a major player in diagnostics and screening in France, specialised across the entire fields of medical biology and anatomical pathology, with a network of 26 multiple-site laboratories. With nearly 400 sites located throughout France, the INOVIE group is the second-largest player in general biology and the third-largest player in specialised biology, with 50 technical facilities serving more than 50,000 patients a day. INOVIE performs specialised analysis in areas of expertise covering molecular biology and genomics (IMAGENOME), diagnosis and treatment of infertility (INOVIE FERTILITE), biological veterinary analysis (INOVIE VET), and anatomical pathology (INOPATH). It also operates outside of France through subsidiaries in the Middle East (INOVIE MENA) and Africa (INOVIE AFRICA). For more information, see www.inovie.fr

Contacts:

INOVIE - Communications Department
Floriane Moine
Email: floriane.moine@inovie.fr

AGENCE PRPA - Press relations
Danielle Maloubier
Email: danielle.maloubier@prpa.fr
Tel.: +33 (0)6 24 26 57 90